Updating results

13 results for brentuximab

Sort: Relevance | Date

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory CD30-positive Hodgkin lymphoma in adults

Technology appraisal guidance Published June 2018

Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults

Technology appraisal guidance Published April 2019

Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults

Technology appraisal guidance Published October 2017

Non-Hodgkin's lymphoma

Everything NICE has said on diagnosing and managing non-Hodgkin's lymphoma in adults and young people 16 years and older in an interactive flowchart

NICE Pathway Published July 2016 Last updated April 2019

Blood and bone marrow cancers

Everything NICE has said on blood and bone marrow cancers including leukaemia in an interactive flowchart

NICE Pathway Published December 2013 Last updated May 2019

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults

Technology appraisal guidance Published July 2017

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma (cHL) in adults

Technology appraisal guidance Published September 2018

Brentuximab vedotin for untreated advanced Hodgkin lymphoma [1258]

In development [GID-TA10224] Expected publication date: TBC

Technology appraisal guidance In development

Brentuximab vedotin for untreated CD30-positive peripheral T-cell lymphoma ID1586

Proposed [GID-TA10514] Expected publication date: TBC

Technology appraisal guidance Proposed

Block scoping reports

NICE block scoping reports

Published July 2019

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)

This guidance has been updated and replaced by NICE technology appraisal guidance 524.

Technology appraisal guidance Published June 2017

NICE approval for nivolumab provides new treatment for advanced blood cancer

People with an advanced type of blood cancer will benefit from nivolumab on the NHS following approval by NICE.

News Published July 2017

Hundreds of people with blood cancer given more treatment options after NICE recommends three drugs

NICE has recommended three blood cancer drugs, brentuximab vedotin, midostaurin and arsenic trioxide be made available on the NHS.

News Published May 2018